Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC). Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017. Ann Oncol 28 (Supplement 5)(958P), 341. doi:10.1093/annonc/mdx372 Abstract Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice – results from the prospective German TMK cohort study. N Marschner, T Fietz, J Rauh, A Nusch, U Söling, M Frank, L Kruggel, M Jänicke, 2017. The Breast, Volume 36, S45 https://doi.org/10.1016/S0960-9776(17)30688-4… Weiterlesen Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC). Woopen, H., Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Sehouli, J., 2017. Ann Oncol… Weiterlesen